Prenatal clinical assessment of sFlt-1 (Soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio as a diagnostic tool for preeclampsia, pregnancy-induced hypertension, and proteinuria

Geburtshilfe und Frauenheilkunde

Volumn 73, Issue 5, 2013, Pages 440-445

  Lehnen, H ^a   Mosblech, N ^a   Reineke, T ^b   Puchooa, A ^a   Menke Mollers I ^c   Zechner, U ^d   Gembruch, U ^e  

^a Children's Hospital Mönchengladbach   (Germany)

^b DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^c SYNLAB ACADEMY   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

IUGR; PlGF; preeclampsia; pregnancy induced hypertension; proteinuria; sFlt 1

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL VALIDITY; CONTROLLED STUDY; DELIVERY; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNOASSAY; INTRAUTERINE GROWTH RETARDATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREDICTION; PREDICTIVE VALUE; PREECLAMPSIA; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VALIDITY;

EID: 84879074574     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0032-1328601     Document Type: Article

References (22)

1. Brown M. A., Lindheimer M. D., de Swiet M. et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy: 2001; 20 XI XIV
2. American College of Obstetricians and Gynecologists Committee on Obstetric Practice Diagnosis and management of preeclampsia and eclampsia: ACOG practice bulletin, No. 33. Int J Gynecol Obstet: 2002; 77 67 75
3. Koopmans C. M., Bijlenga D., Groen H. et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks gestation (HYPITAT): a multicenter, open-label randomized controlled trial. Lancet: 2009; 374 979 988
4. Magee L. A., Yong J., Espinosa V. et al. Expectant management of severe preeclampsia remote from term: a structured systematic review. Hypertens Pregnancy: 2009; 28 312 347
5. Dvorak H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol: 2002; 20 4368 4380
6. Karumanchi S. A., Lim K. H., August P. Pathogenesis of preeclampsia. Up to date, last literature review version 19.3 Sept 2011.
7. Levine R. J., Maynard S. E., Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med: 2004; 350 672 683
8. Verlohren S., Galindo A., Schlembach D. et al. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol: 2010; 202 161.e1 161.e11
9. Elecsys, Penzberg, Germany. http://www.roche.de/diagnostics/labor/ serumarbeitsplatz/praeeklampsie.htm
10. Maynard S. E., Min J. Y., Merchan J. et al. Express placental soluble fms-like tyrosine kinase-1 (sFLT-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest: 2003; 111 649 658
11. Chaiworapongsa T., Romero R., Espinoza J. et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol: 2004; 190 1541 1547
12. Mehendale R., Hibbard J., Fazleabas A. et al. Placental angiogenesis markers sFlt-1 and PlGF: response to cigarette smoke. Am J Obstet Gynecol: 2007; 197 363.e1 363.e5
13. Widmer M., Villar J., Benigni A. et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol: 2007; 109 168 180
14. Tallarek A-C, Huppetz B., Stepan H. Preeclampsia - aetiology, current diagnostics and clinical management, new therapy options and future perspectives. Geburtsh Frauenheilk: 2012; 72 1099 1106
15. Verlohren S., Herraiz I., Lapaire O. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol: 2012; 206 58.e1 58.e8
16. Rana S., Hacker M. R., Modest A. M. et al. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension: 2012; 60 451 458
17. Rana S., Powe C. E., Salahuddin S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation: 2012; 125 911 919
18. Espinoza J., Romero R., Nien J. K. et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am Obstet Gynecol: 2007; 196 326.e1 326.e13
19. Benton S. J., Hu Y., Xie F. et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol: 2011; 205 469 471
20. De Oliveira L., Camara N. OS, Peracoli J. C. et al. SFlt-1 and IP-10 in women with early-onset preeclampsia. Pregnancy Hypertension: 2011; 1 129 131
21. Knudsen U. B., Kronborg C. S., von Dadelszen P. et al. A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertension: 2012; 2 8 15
22. Ghosh S. K., Raheja S., Tuli A. et al. Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preeclampsia and/or early onset intrauterine growth restriction? A prospective cohort study. J Obstet Gynaecol Res: 2013; Mar 17 [Epub ahead of print]